Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
6 hedge funds and large institutions have $10.5M invested in Celyad Oncology SA American Depositary Shares in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
54% more capital invested
Capital invested by funds: $6.8M → $10.5M (+$3.66M)
0% more funds holding
Funds holding: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$492K |
| 2 |
Morgan Stanley
New York
|
+$12.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.55K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$218 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$192K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $9.99M | +$492K | +22,600 | +6% |
|
|
DCM
2
DAFNA Capital Management
Los Angeles,
California
| $328K | – | – | – |
|
|
3
Morgan Stanley
New York
| $83K | +$12.2K | +562 | +22% |
|
|
4
Zurich Cantonal Bank
Zurich,
Switzerland
| $42K | -$192K | -8,833 | -85% |
|
|
5
UBS Group
Zurich,
Switzerland
| $11K | +$7.55K | +347 | +542% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $9K | +$218 | +10 | +3% |
|
CYAD Hedge Fund Activity: Q1 2017 in Review
6 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q1 2017, worth a combined $10.5M — up 54% from $6.8M a quarter earlier.
Fund positioning in CYAD was balanced in Q1 2017: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $492K. The largest seller was Zurich Cantonal Bank, cutting an estimated $192K.
- 6 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $10.5M of Celyad Oncology SA American Depositary Shares stock for Q1 2017, up 54% quarter-over-quarter.
- 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q1 2017 and 0 closed out.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q1 2017 was Victory Capital Management, an estimated $492K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q1 2017 was Zurich Cantonal Bank, an estimated $192K sold.
Based on aggregated 13F filings for Q1 2017.